|
|
||||||||
Eur J Cardiothorac Surg 2004;26:S54-S56
© 2004 Elsevier Science NL
Review |
Institut für Neurophysiologie, University of Cologne, Robert-Koch-Str. 39, 50931 Köln, Germany
* Corresponding author. Tel.: +49 221 478 6960; fax: +49 221 478 6965. (Email: j.hescheler{at}uni-koeln.de).
Replacement of damaged myocardium with electrically functional, contracting syncytium with a balanced blood supply remains a key goal for the treatment of hearts damaged by coronary heart disease or other disorders. Stem cell therapy offers a potential solution. This paper describes the value of in vitro stem cell research to unravel the roles of key regulatory molecules in embryogenesis of myocardium and blood vessels. Studies have shown that functioning myocytes can be derived from stem cells in vitro and engrafted into infarcted areas of heart where they develop into functional adult like cardiomyocytes with action potentials and capacity for beta adrenergic and muscarinic regulation. Further studies have identified specific roles for platelet endothelial cell adhesion molecule (PECAM), vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF) in the sequential differentiation of blood vessels and capillaries.
Key Words: Angiogenesis Cardiomyocyte Embryonic stem cells Vascular endothelial growth factor Platelet endothelial cell adhesion molecule Fibroblast growth factor
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |